Dr Reddy’s Laboratories (DRL) announced its audited consolidated financial results for the fourth quarter and full year ended March 31, 2013 under International Financial Reporting Standards (IFRS). The consolidated revenues for FY13 has been posted at Rs 116.3 billion, recorded year-on-year growth of 20 per cent. Excluding the beneficial impact of olanzapine exclusivity in FY12, registered year-on-year growth of 26 per cent. Growth primarily driven by North America and emerging markets (which include Russia, other CIS countries and Rest of World (RoW) territories) in the global generics segment; and overall performance by pharmaceutical services and active ingredients segment.
The consolidated revenues were reported at Rs 33.4 billion in Q4 FY13, showing an year-on-year growth of 26 per cent. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of Rs 27.8 billion was reported in FY13 with year-on-year growth of 9.5 per cent. EBITDA of Rs 9.3 billion in Q4 FY13, 28% of revenues has been posted, with year-on-year growth of 37 per cent. Profit after tax (PAT) for FY13 is at Rs 17.5 billion, with an year-on-year growth of 17 per cent. Profit after tax of Rs 5.7 billion in Q4 FY13 has been posted with an year-on-year growth of 67 per cent.
EP News Bureau – Mumbai
